| Literature DB >> 24564909 |
Hui Yu, Chen-Ching Lin, Yuan-Yuan Li, Zhongming Zhao.
Abstract
BACKGROUND: Gene expression profiles have been frequently integrated with the human protein interactome to uncover functional modules under specific conditions like disease state. Beyond traditional differential expression analysis, differential co-expression analysis has emerged as a robust approach to reveal condition-specific network modules, with successful applications in a few human disease studies. Hepatocellular carcinoma (HCC), which is often interrelated with the Hepatitis C virus, typically develops through multiple stages. A comprehensive investigation of HCC progression-specific differential co-expression modules may advance our understanding of HCC's pathophysiological mechanisms.Entities:
Mesh:
Year: 2013 PMID: 24564909 PMCID: PMC4029569 DOI: 10.1186/1752-0509-7-S5-S2
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1Differential co-expression analysis of protein interaction network for human hepatocellular carcinoma (HCC) progression. Four arrows in this figure indicate major analysis flow. Arrow 1: for each protein interaction pair (edge), an expression correlation value was calculated for each of five HCC stages, and a differential correlation value (dC) was calculated for each of four stage transitions. Edges with the highest dC values were used as seeds in a search of a differential co-expression subnetwork. Four subnetworks were retrieved from the PIN for the four HCC stage transitions, respectively. Arrow 2: the four transition-wise subnetworks were combined into a union set, in which each edge was associated with four dC values. Arrow 3: the edges in the union subnetwork were clustered based on similarity in those four-dC data vectors. Arrow 4: six clusters of differential co-expression protein-interaction modules were determined, each characterized with a distinct, coherent co-expression change pattern over the whole HCC process.
Proportion of Hepatitis C virus-binding proteins in top ranked gene seeds
| Top levela | Gene set | HCC transitionb | |||
|---|---|---|---|---|---|
| N-C | C-D | D-E | E-A | ||
| 0.1% | DEG | 0/11 | 1/11 | 0/11 | 1/11 |
| DCG | 7/63* | 9/65*** | 10/60*** | 4/63 | |
| 0.5% | DEG | 3/55 | 2/55 | 2/55 | 4/55 |
| DCG | 25/290*** | 36/279*** | 27/287*** | 27/288*** | |
| 1.0% | DEG | 6/110 | 3/110 | 5/110 | 6/110 |
| DCG | 47/524*** | 51/538*** | 36/523*** | 41/559*** | |
In each cell, the proportion is shown as ″x/y″, with y for top-ranked genes and × for genes of interest. Enrichment p-value < 0.01 (*) or < 0.0001 (***) are marked.
aTop-level is the fraction of the top-ranked genes/pairs in the total network nodes/edges. For differential expression genes (DEG), we used the node-wise fraction; for differential co-expression genes (DCGs) deriving from pairs, we used the edge-wise fraction. A same fraction of pairs involve a greater number of genes.
bTransition names: Normal to Cirrhosis (N-C), Cirrhosis to Dysplasia (C-D), Dysplasia to Early HCC (D-E), and Early HCC to Advanced HCC (E-A).
Average shortest length among top ranked genes
| Top level | Gene set | HCC transition | |||
|---|---|---|---|---|---|
| N-C | C-D | D-E | E-A | ||
| 0.1% | DEG | 3.61 ± 0.59 | 3.25 ± 0.86 | 3.40 ± 0.91 | 4.25 ± 0.86 |
| DCG | 2.96 ± 0.71 | 2.94 ± 0.74 | 2.72 ± 0.75 | 2.98 ± 0.75 | |
| 0.5% | DEG | 3.70 ± 0.78 | 3.62 ± 0.85 | 3.76 ± 0.82 | 3.62 ± 0.85 |
| DCG | 2.89 ± 0.71 | 2.81 ± 0.68 | 2.82 ± 0.73 | 2.89 ± 0.70 | |
| 1.0% | DEG | 3.60 ± 0.81 | 3.63 ± 0.84 | 3.67 ± 0.81 | 3.60 ± 0.87 |
| DCG | 2.87 ± 0.69 | 2.85 ± 0.76 | 2.86 ± 0.70 | 2.90 ± 0.71 | |
There were 3.6% , 10.7% , 1.8%, or 5.4%disconnected DEG pairs and they were excluded from the average shortest length calculation.
Transition-wise differential co-expression protein interaction subnetworks
| Transition | # nodes | # edges | ||||
|---|---|---|---|---|---|---|
| HCB | CGC | HCR | ||||
| N-C | 307 | 310 | 28 | 29 | 154 |
ARRB1, |
| C-D | 102 | 103 | 13 | 10 | 44 | |
| D-E | 104 | 103 | 10 | 13 | 58 | |
| E-A | 103 | 102 | 9 | 11 | 60 | |
aSee Materials and methods for explanation of the three HCC-related gene sets. Significance levels of HCC-related gene enrichment are labeled by *(p < 0.01) and ***(p < 0.0001).
bHubs are genes with six or more connected neighbors. Hepatitis C virus -binding genes (italicized) and cancer-mutated genes (bold) are marked.
Figure 2APC-centered protein interaction module characteristic for dynamic co-expression patterns over hepatocellular carcinoma precancerous stages. Edge widths are proportional to the expression correlation values (edge weights). Red edge: positive expression correlation; green edge: negative expression correlation. Light gray node: non-differential expression; dark gray node: up-regulation (t-test, p < 0.05); white node: down-regulation (t-test, p < 0.05).
Figure 3Expression correlation change patterns of six clusters of differential co-expression protein interaction modules. Abscissa includes five Hepatocellular carcinoma (HCC) stages: Normal (N), Cirrhosis (C), Dysplasia (D), E (Early HCC), and A (Advanced HCC).
Six clusters of process-wise differential co-expression protein interaction modules
| Cluster ID | # node | # edge | # components | Size of largest component | # HCV-binding genes |
|---|---|---|---|---|---|
| I | 96 | 87 | 10 | 13 | 6 |
| II | 40 | 36 | 4 | 20 | 9*** |
| III | 122 | 112 | 10 | 21 | 14*** |
| IV | 60 | 56 | 4 | 19 | 8 * |
| V | 21 | 18 | 3 | 7 | 3 * |
| VI | 20 | 18 | 2 | 13 | 2 |
Hepatitis C virus (HCV)-binding protein enrichment significance levels: * for p < 0.01 and *** for p < 0.0001.
Gene Ontology (GO) Biological Processes enriched in clusters of differential co-expression protein interaction modules
| Cluster | GOID | Term | # expec-ted genes | # genes | Adjusted |
|---|---|---|---|---|---|
| I | GO:0071842 | cellular component organization at cellular level | 23.3 | 44 | 0.0002 |
| I | GO:0007346 | regulation of mitotic cell cycle | 2.6 | 12 | 0.0004 |
| I | GO:2000241 | regulation of reproductive process | 1.2 | 8 | 0.0006 |
| I | GO:0009968 | negative regulation of signal transduction | 4.3 | 15 | 0.0006 |
| I | GO:0043066 | negative regulation of apoptotic process | 4.9 | 16 | 0.0006 |
| I | GO:0031577 | spindle checkpoint | 0.4 | 5 | 0.0007 |
| I | GO:0032088 | negative regulation of NF-kappaB transcription factor activity | 0.4 | 5 | 0.0007 |
| I | GO:0000086 | G2/M transition of mitotic cell cycle | 1.3 | 8 | 0.0007 |
| I | GO:0048522 | positive regulation of cellular process | 23.2 | 41 | 0.0007 |
| I | GO:0006366 | transcription from RNA polymerase II promoter | 10.2 | 24 | 0.0007 |
| I | GO:0042221 | response to chemical stimulus | 20.2 | 37 | 0.0008 |
| I | GO:0031623 | receptor internalization | 0.4 | 5 | 0.0008 |
| I | GO:0048468 | cell development | 10.5 | 24 | 0.0008 |
| I | GO:0050658 | RNA transport | 1.0 | 7 | 0.0008 |
| I | GO:0016032 | viral reproduction | 3.7 | 13 | 0.0009 |
| II | GO:0043065 | positive regulation of apoptotic process | 2.0 | 11 | 0.0003 |
| II | GO:0006366 | transcription from RNA polymerase II promoter | 4.3 | 15 | 0.0005 |
| III | GO:0016567 | protein ubiquitination | 4.5 | 17 | 0.0001 |
| III | GO:0000075 | cell cycle checkpoint | 2.7 | 13 | 0.0001 |
| III | GO:0042981 | regulation of apoptotic process | 12.9 | 30 | 0.0001 |
| III | GO:0000165 | MAPK cascade | 4.4 | 16 | 0.0001 |
| III | GO:0032268 | regulation of cellular protein metabolic process | 12.6 | 29 | 0.0001 |
| III | GO:0010627 | regulation of intracellular protein kinase cascade | 5.7 | 18 | 0.0002 |
| III | GO:0050863 | regulation of T cell activation | 2.4 | 11 | 0.0002 |
| III | GO:0007346 | regulation of mitotic cell cycle | 3.3 | 13 | 0.0002 |
| III | GO:0044419 | interspecies interaction between organisms | 4.4 | 15 | 0.0003 |
| III | GO:0006511 | ubiquitin-dependent protein catabolic process | 4.0 | 14 | 0.0003 |
| III | GO:0045892 | negative regulation of transcription, DNA-dependent | 7.7 | 20 | 0.0005 |
| III | GO:0007265 | Ras protein signal transduction | 2.8 | 11 | 0.0006 |
| III | GO:0007173 | epidermal growth factor receptor signaling pathway | 1.9 | 9 | 0.0007 |
| III | GO:0051090 | regulation of sequence-specific DNA binding transcription factor activity | 3.3 | 12 | 0.0007 |
| III | GO:0009967 | positive regulation of signal transduction | 6.7 | 18 | 0.0007 |
| III | GO:0016310 | phosphorylation | 13.6 | 28 | 0.0008 |
| III | GO:0045732 | positive regulation of protein catabolic process | 0.8 | 6 | 0.0008 |
| III | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 1.1 | 7 | 0.0008 |
| III | GO:0042770 | signal transduction in response to DNA damage | 1.5 | 8 | 0.0009 |
| III | GO:0080134 | regulation of response to stress | 6.9 | 18 | 0.0009 |
| III | GO:0008285 | negative regulation of cell proliferation | 5.1 | 15 | 0.0009 |
| IV* | GO:0044419 * | interspecies interaction between organisms | 2.1 | 11 | 0.0020 |
| IV* | GO:0000904 * | cell morphogenesis involved in differentiation | 3.3 | 12 | 0.0099 |
| IV* | GO:0007165 * | signal transduction | 18.8 | 33 | 0.0099 |
| V | GO:0065008 | regulation of biological quality | 4.1 | 13 | 0.0008 |
| V | GO:0001775 | cell activation | 1.4 | 8 | 0.0009 |
| V | GO:0018193 | peptidyl-amino acid modification | 1.0 | 7 | 0.0009 |
| V | GO:0048011 | nerve growth factor receptor signaling pathway | 0.5 | 5 | 0.0009 |
| V | GO:0043066 | negative regulation of apoptotic process | 1.1 | 7 | 0.0009 |
| V | GO:0000165 | MAPK cascade | 0.8 | 6 | 0.0009 |
| V | GO:0042060 | wound healing | 1.2 | 7 | 0.0009 |
| V | GO:0045860 | positive regulation of protein kinase activity | 0.8 | 6 | 0.0009 |
| V | GO:0071375 | cellular response to peptide hormone stimulus | 0.5 | 5 | 0.0009 |
*Threshold value for adjusted p-value is 0.01 (Cluster IV) or 0.001 (clusters I, II, III, and V). No GO term was found to be enriched for cluster VI with either threshold value.
Figure 4Thirty-three interactions of YWHAZ were categorized into six clusters based on their dynamic co-transcription profiles. Hepatitis C virus protein-binding genes (in red), hepatocellular carcinoma-responsive genes (in pink), and cancer-mutated genes (*) were marked.